5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
ALT O
Elevations O
: O
Discontinue O
ethinyl O
estradiol-containing O
medications O
prior O
to O
starting O
VIEKIRA O
PAK O
( O
alternative O
contraceptive O
methods O
are O
recommended O
) O
. O

Perform O
hepatic O
laboratory O
testing O
on O
all O
patients O
during O
the O
first O
4 O
weeks O
of O
treatment O
. O

For O
ALT O
elevations O
on O
VIEKIRA O
PAK O
, O
monitor O
closely O
and O
follow O
recommendations O
in O
full O
prescribing O
information O
. O

( O
5.1 O
) O
* O
Risks O
Associated O
With O
Ribavirin O
Combination O
Treatment O
: O
If O
VIEKIRA O
PAK O
is O
administered O
with O
ribavirin O
, O
the O
warnings O
and O
precautions O
for O
ribavirin O
also O
apply O
to O
this O
combination O
regimen O
. O

( O
5.2 O
) O
* O
Drug O
Interactions O
: O
The O
concomitant O
use O
of O
VIEKIRA O
PAK O
and O
certain O
other O
drugs O
may O
result O
in O
known O
or O
potentially O
significant O
drug O
interactions O
, O
some O
of O
which O
may O
lead O
to O
loss O
of O
therapeutic O
effect O
of O
VIEKIRA O
PAK O
. O

( O
5.3 O
) O
5.1 O
Increased O
Risk O
of O
ALT O
Elevations O
During O
clinical O
trials O
with O
VIEKIRA O
PAK O
with O
or O
without O
ribavirin O
, O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
to O
greater O
than O
5 O
times O
the O
upper O
limit O
of O
normal O
( O
ULN O
) O
occurred O
in O
approximately O
1 O
% O
of O
all O
subjects O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
were O
typically O
asymptomatic O
, O
occurred O
during O
the O
first O
4 O
weeks O
of O
treatment O
, O
and O
declined O
within O
two O
to O
eight O
weeks O
of O
onset O
with O
continued O
dosing O
of O
VIEKIRA O
PAK O
with O
or O
without O
ribavirin O
. O

These O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
were O
significantly O
more O
frequent O
in O
female O
subjects O
who O
were O
using O
ethinyl O
estradiol-containing O
medications O
such O
as O
combined O
oral O
contraceptives O
, O
contraceptive O
patches O
or O
contraceptive O
vaginal O
rings O
. O

Ethinyl O
estradiol-containing O
medications O
must O
be O
discontinued O
prior O
to O
starting O
therapy O
with O
VIEKIRA O
PAK O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

Alternative O
methods O
of O
contraception O
( O
e.g O
, O
progestin O
only O
contraception O
or O
non-hormonal O
methods O
) O
are O
recommended O
during O
VIEKIRA O
PAK O
therapy O
. O

Ethinyl O
estradiol-containing O
medications O
can O
be O
restarted O
approximately O
2 O
weeks O
following O
completion O
of O
treatment O
with O
VIEKIRA O
PAK O
. O

Women O
using O
estrogens O
other O
than O
ethinyl O
estradiol O
, O
such O
as O
estradiol O
and O
conjugated O
estrogens O
used O
in O
hormone O
replacement O
therapy O
had O
a O
rate O
of O
ALT B-NonOSE_AE
elevation I-NonOSE_AE
similar O
to O
those O
not O
receiving O
any O
estrogens O
; O
however O
, O
due O
to O
the O
limited O
number O
of O
subjects O
taking O
these O
other O
estrogens O
, O
caution O
is O
warranted O
for O
co-administration O
with O
VIEKIRA O
PAK O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Hepatic O
laboratory O
testing O
should O
be O
performed O
during O
the O
first O
4 O
weeks O
of O
starting O
treatment O
and O
as O
clinically O
indicated O
thereafter O
. O

If O
ALT B-NonOSE_AE
is I-NonOSE_AE
found I-NonOSE_AE
to I-NonOSE_AE
be I-NonOSE_AE
elevated I-NonOSE_AE
above O
baseline O
levels O
, O
it O
should O
be O
repeated O
and O
monitored O
closely O
: O
* O
Patients O
should O
be O
instructed O
to O
consult O
their O
health O
care O
professional O
without O
delay O
if O
they O
have O
onset O
of O
fatigue B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
lack B-NonOSE_AE
of I-NonOSE_AE
appetite I-NonOSE_AE
, O
nausea B-NonOSE_AE
and O
vomiting B-NonOSE_AE
, O
jaundice B-NonOSE_AE
or O
discolored B-NonOSE_AE
feces I-NonOSE_AE
. O

* O
Consider O
discontinuing O
VIEKIRA O
PAK O
if O
ALT B-NonOSE_AE
levels I-NonOSE_AE
remain I-NonOSE_AE
persistently I-NonOSE_AE
greater I-NonOSE_AE
than I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
times I-NonOSE_AE
the I-NonOSE_AE
ULN I-NonOSE_AE
. O

* O
Discontinue O
VIEKIRA O
PAK O
if O
ALT B-NonOSE_AE
elevation I-NonOSE_AE
is O
accompanied O
by O
signs O
or O
symptoms O
of O
liver B-NonOSE_AE
inflammation I-NonOSE_AE
or O
increasing B-NonOSE_AE
conjugated I-NonOSE_AE
bilirubin I-NonOSE_AE
, O
alkaline O
phosphatase O
, O
or O
INR O
. O

5.2 O
Risks O
Associated O
With O
Ribavirin O
Combination O
Treatment O
If O
VIEKIRA O
PAK O
is O
administered O
with O
ribavirin O
, O
the O
warnings O
and O
precautions O
for O
ribavirin O
, O
in O
particular O
the O
pregnancy B-NonOSE_AE
avoidance O
warning O
, O
apply O
to O
this O
combination O
regimen O
. O

Refer O
to O
the O
ribavirin O
prescribing O
information O
for O
a O
full O
list O
of O
the O
warnings O
and O
precautions O
for O
ribavirin O
. O

5.3 O
Risk O
of O
Adverse O
Reactions O
or O
Reduced O
Therapeutic O
Effect O
Due O
to O
Drug O
Interactions O
The O
concomitant O
use O
of O
VIEKIRA O
PAK O
and O
certain O
other O
drugs O
may O
result O
in O
known O
or O
potentially O
significant O
drug O
interactions O
, O
some O
of O
which O
may O
lead O
to O
: O
* O
Loss O
of O
therapeutic O
effect O
of O
VIEKIRA O
PAK O
and O
possible O
development B-NonOSE_AE
of I-NonOSE_AE
resistance I-NonOSE_AE
* O
Possible O
clinically O
significant O
adverse O
reactions O
from O
greater O
exposures O
of O
concomitant O
drugs O
or O
components O
of O
VIEKIRA O
PAK O
. O

See O
Table O
5 O
for O
steps O
to O
prevent O
or O
manage O
these O
possible O
and O
known O
significant O
drug O
interactions O
, O
including O
dosing O
recommendations O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

Consider O
the O
potential O
for O
drug O
interactions O
prior O
to O
and O
during O
VIEKIRA O
PAK O
therapy O
; O
review O
concomitant O
medications O
during O
VIEKIRA O
PAK O
therapy O
; O
and O
monitor O
for O
the O
adverse O
reactions O
associated O
with O
the O
concomitant O
drugs O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Drug O
Interactions O
( O
7 O
) O
] O
. O

5.4 O
Risk O
of O
HIV-1 O
Protease O
Inhibitor O
Drug O
Resistance O
in O
HCV/HIV-1 O
Co-infected O
Patients O
The O
ritonavir O
component O
of O
VIEKIRA O
PAK O
is O
also O
an O
HIV-1 O
protease O
inhibitor O
and O
can O
select B-OSE_Labeled_AE
for I-OSE_Labeled_AE
HIV I-OSE_Labeled_AE
- I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
protease I-OSE_Labeled_AE
inhibitor I-OSE_Labeled_AE
resistance I-OSE_Labeled_AE
- I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
substitutions I-OSE_Labeled_AE
. O

Any O
HCV B-Not_AE_Candidate
/ O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
1 I-Not_AE_Candidate
co-infected O
patients O
treated O
with O
VIEKIRA O
PAK O
should O
also O
be O
on O
a O
suppressive O
antiretroviral O
drug O
regimen O
to O
reduce O
the O
risk O
of O
HIV B-NonOSE_AE
- I-NonOSE_AE
1 I-NonOSE_AE
protease I-NonOSE_AE
inhibitor I-NonOSE_AE
drug I-NonOSE_AE
resistance I-NonOSE_AE
. O

